Elizabeth Rozek's most recent trade in Sagimet Biosciences Inc - Ordinary Shares - Class A was a trade of 10,780 Series A Common Stock done at an average price of $9.1 . Disclosure was reported to the exchange on July 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc | Elizabeth Rozek | General Counsel and CCO | Sale of securities on an exchange or to another person at price $ 9.13 per share. | 21 Jul 2025 | 10,780 | 183,726 | - | 9.1 | 98,471 | Series A Common Stock |
| Sagimet Biosciences Inc | Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 138,000 | 138,000 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc | Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 34,000 | 194,506 | - | 0 | Series A Common Stock | |
| Sagimet Biosciences Inc | Elizabeth Rozek | General Counsel and CCO | Sale of securities on an exchange or to another person at price $ 3.10 per share. | 19 Jul 2024 | 10,914 | 160,506 | - | 3.1 | 33,830 | Series A Common Stock |
| Sagimet Biosciences Inc | Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 242,142 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc | Elizabeth Rozek | General Counsel and CCO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 0 | - | - | Stock Option (Right to Buy) |